Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4736 (Durvalumab) in Advanced Solid Tumors
NCT01693562Phase 2Completed
- Sponsor
- MedImmune
- Start
- Sep 2012
- Primary completion
- Feb 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 9
01
Overview
Phase 2, open-label trial of durvalumab in solid tumor (advanced stage), squamous cell carcinoma of the head and neck (HNSCC), non-small cell lung cancer (NSCLC) and 13 more (23 arms), sponsored by MedImmune. Primary endpoints: Dose-limiting Toxicities at 42 days, Treatment-emergent Adverse Events and 4 more. Started Sep 2012; status: completed.
02
Drugs
durvalumab
03
Conditions
solid tumor (advanced stage)squamous cell carcinoma of the head and neck (HNSCC)non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)melanoma
Beyond the preview
Go deeper on NCT01693562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01693562.